Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1999 1
2004 2
2007 4
2008 2
2009 2
2010 1
2012 1
2013 3
2014 3
2015 2
2016 3
2018 5
2019 1
2020 4
2021 6
2022 4
2023 5
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: ferrant e. Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1. Leukemia. 2022. PMID: 34974526 Free PMC article. No abstract available.
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.
Guièze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Drénou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, Véronèse L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P. Guièze R, et al. Among authors: ferrant e. Nat Commun. 2024 Aug 9;15(1):6822. doi: 10.1038/s41467-024-51264-2. Nat Commun. 2024. PMID: 39122717 Free PMC article. Clinical Trial.
[Angiogenesis targeting in breast cancer].
Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E. Fumoleau P, et al. Among authors: ferrant e. Bull Cancer. 2007;94(7 Suppl):F199-206. Bull Cancer. 2007. PMID: 17964997 Review. French.
Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy.
Robak T, Doubek M, Ferrant E, Diels J, Andersone L, Wilbertz S, Healy NC, Neumayr L, van Sanden S. Robak T, et al. Among authors: ferrant e. Curr Med Res Opin. 2024 Aug;40(8):1369-1378. doi: 10.1080/03007995.2024.2368175. Epub 2024 Jul 1. Curr Med Res Opin. 2024. PMID: 38885086 Free article. Clinical Trial.
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Michallet AS, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy MS, Morisset S, Rouille V, Mahé B, Laribi K, Villemagne B, Ferrant E, Tournilhac O, Delmer A, Molina L, Leblond V, Tomowiak C, de Guibert S, Orsini-Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Schleinitz TA, Cymbalista F, Leprêtre S, Lévy V, Nguyen-Khac F, Feugier P. Michallet AS, et al. Among authors: ferrant e. Blood Adv. 2023 Aug 8;7(15):3936-3945. doi: 10.1182/bloodadvances.2022009594. Blood Adv. 2023. PMID: 37026799 Free PMC article. Clinical Trial.
[Retrospective study of 25 cases of pulmonary mucormycosis in acute leukaemia].
Caillot D, Legouge C, Lafon I, Ferrant E, Pagès PB, Plocque A, Estivalet L, Valot S, Dalle F, Abou Hanna H, Chretien ML. Caillot D, et al. Among authors: ferrant e. Rev Mal Respir. 2018 Apr;35(4):452-464. doi: 10.1016/j.rmr.2017.11.009. Epub 2018 May 10. Rev Mal Respir. 2018. PMID: 29754839 Review. French.
49 results